New Study Reveals Grim GvHD Reality, Spotlighting Microbiome Therapy Hope

LYON, France – April 01, 2026 – A major new study published in the prestigious Bone Marrow Transplantation journal has cast a harsh light on the grim prognosis for patients battling the most severe forms of acute Graft-versus-Host Disease (aGvHD), a deadly complication of stem cell transplants. The study, known as CHRONOS, reveals that patients who have failed two prior lines of therapy face a median survival of just 86 days, with only 29% of patients surviving for one year.

These stark figures establish a crucial, contemporary benchmark for a condition that has long lacked standardized treatments and effective options. However, the data also serves a strategic purpose: to contextualize the dramatically more promising results from a new class of treatment. French biotech company MaaT Pharma, which sponsored the CHRONOS study, has positioned its microbiome-based therapy, MaaT013 (Xervyteg®), as a potential solution, backed by clinical trial data showing it more than doubles the one-year survival rate compared to the new benchmark.

A Desperate Need for New Options

Acute GvHD occurs when immune cells from a donor's stem cell transplant attack the recipient's body. While initially life-saving, the transplant can turn deadly, causing severe inflammation of the skin, liver, and gastrointestinal (GI) tract. The standard of care begins with corticosteroids, but up to 60% of patients fail to respond. For them, the next step is ruxolitinib, a JAK inhibitor approved as a second-line treatment.

For the unfortunate patients who fail both steroids and ruxolitinib, the path forward becomes dangerously unclear. There are no approved third-line therapies, leaving clinicians to rely on a patchwork of off-label treatments with limited and often fleeting success. The CHRONOS study, which retrospectively analyzed 59 such patients across 16 European transplant centers, confirms this chaotic and ineffective landscape. The study found that twelve different therapies were used, with none demonstrating significant or lasting benefit.

Key findings from CHRONOS underscore the severity of the challenge:

• Poor Initial Response: The overall response rate at Day 28 across all organs was just 36%.
• Rapid Loss of Efficacy: By Day 56, the response rate had plummeted to 20%, indicating that even when a treatment initially works, its effects are short-lived.
• Dire Survival: The median overall survival was less than three months (86 days), with a 12-month survival rate of just 29%.

“CHRONOS provides a contemporary reference point for third-line GI-aGvHD, underscoring both the gravity of this condition and the persistent lack of standardized, effective therapies,” said Dr. Johannes Clausen, a hematologist at Ordensklinikum Linz Elisabethinen in Austria and the study's primary author. “The study highlights the stark limitations of current options and sets a meaningful new benchmark for this challenging clinical setting.”

Strategic Science: Setting a New Benchmark

The publication of the CHRONOS data is a key move in MaaT Pharma's strategy to bring its novel therapy to market. By funding a study that defines the bleakness of the current standard of care, the company has created an official, data-backed reference point against which its own drug can be measured. This use of real-world evidence is becoming increasingly important in drug development, especially for rare and life-threatening diseases where running large, placebo-controlled trials can be ethically and practically challenging.

This real-world data provides regulatory bodies, like the European Medicines Agency (EMA), with the critical context needed to evaluate the true clinical benefit of a new therapeutic. It answers the fundamental question for any new drug: Is it better than what is currently available? The CHRONOS data provides a clear and sobering answer about the current landscape, making the case for innovation all the more urgent.

A Microbiome Therapy Emerges as a Beacon of Hope

Against this grim backdrop, the results for MaaT013 (Xervyteg®) from its pivotal ARES trial appear transformative. MaaT013 is not a typical drug; it is a Microbiome Ecosystem Therapy (MET), a full-ecosystem, off-the-shelf product derived from pooled healthy donors. Administered as an enema, it is designed to restore a patient's dysbiotic, or imbalanced, gut microbiome. The scientific rationale is that by reintroducing a diverse and healthy community of microbes, the therapy can repair the gut-immune axis, taming the hyperactive immune response that drives aGvHD.

The clinical data comparing the ARES trial to the CHRONOS benchmark is striking:

• Superior Response: The ARES trial reported a 62% GI overall response rate at Day 28, substantially higher than the 37% seen in CHRONOS.
• Durable Efficacy: Unlike the rapid decline seen with existing therapies, the response to MaaT013 was maintained, with a 47% GI response rate at Day 56.
• Dramatically Improved Survival: Most impressively, the 12-month overall survival in the ARES trial was 54%, nearly double the 29% reported in CHRONOS. The median overall survival was not even reached, indicating that a majority of patients were still alive at the end of the follow-up period.

“Acute GvHD remains a devastating disease with a profound unmet medical need,” stated Prof. Florent Malard of Saint-Antoine Hospital and Sorbonne University, the lead investigator of the ARES trial. “By providing an updated and credible benchmark, CHRONOS offers critical context to interpret the results of the pivotal ARES trial and the potential clinical benefit observed with MaaT013.”

The Path Toward a New Standard of Care

MaaT Pharma has already submitted its Marketing Authorization Application for MaaT013 to the EMA in June 2025, with a decision anticipated by mid-2026. If approved, it would be the first microbiome-based therapy authorized in Europe for an oncology indication and the first approved treatment specifically for this desperate patient population. The therapy has already received Orphan Drug Designation in both Europe and the United States, a status that facilitates the development of drugs for rare diseases.

The company is also preparing for a potential commercial launch in Europe in 2026, partnering with Clinigen to manage early access and distribution. This proactive planning signals strong confidence in the therapy's potential to become a new standard of care.

The convergence of the CHRONOS and ARES data represents a pivotal moment for patients with refractory aGvHD. One study has definitively quantified the failure of current approaches, while another offers a scientifically novel and clinically powerful solution. For thousands of patients who undergo stem cell transplants each year, this development could represent the first real hope for survival after all other options have been exhausted.